Sign Up
Stories
Collaboration Enhances Cardio-Renal Study
Share
89bio to Present pegozafermin for NASH a...
Advancements in Cancer Treatment and Mar...
Alpha-1 Antitrypsin Deficiency Epidemiol...
4D Molecular Therapeutics Raises $300 Mi...
AI-Powered Cancer Drug Trials
ANJESO Drug Insight and Market Forecast
Overview
API
Saghmos Therapeutics collaborates with Duke Clinical Research Institute to enhance Phase 3 study for cardio-renal metabolic modulator ST-62516, aiming to mitigate risks post-PCI procedures.
Ask a question
How could the outcomes of this collaboration impact the broader landscape of cardiovascular research and patient care?
How might the collaboration between Saghmos Therapeutics and DCRI influence future treatments for cardio-renal conditions?
What specific methodologies or innovations are expected to emerge from the optimized Phase 3 study?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Coverage